251 related articles for article (PubMed ID: 8853257)
21. Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors.
Drougas JG; Anthony LB; Blair TK; Lopez RR; Wright JK; Chapman WC; Webb L; Mazer M; Meranze S; Pinson CW
Am J Surg; 1998 May; 175(5):408-12. PubMed ID: 9600289
[TBL] [Abstract][Full Text] [Related]
22. Repetitive chemoembolization with melphalan plus intra-arterial immuno-chemotherapy within 5-fluorouracil and granulocyte-macrophage colony-stimulating factor (GM-CSF) as effective first- and second-line treatment of disseminated colorectal liver metastases.
Müller H; Nakchbandi V; Chatzisavvidis I; von Voigt C
Hepatogastroenterology; 2003; 50(54):1919-26. PubMed ID: 14696433
[TBL] [Abstract][Full Text] [Related]
23. [Effective treatment of a hormonally inactive carcinoid tumour with somatostatin analogues: application of serum chromogranin-A for clinical follow-up].
Igaz P; Rácz K; Tulassay Z
Orv Hetil; 2007 Dec; 148(49):2343-6. PubMed ID: 18048114
[TBL] [Abstract][Full Text] [Related]
24. Intra-arterial infusion of 5-fluorouracil plus granulocyte-macrophage colony-stimulating factor (GM-CSF) and chemoembolization with melphalan in the treatment of disseminated colorectal liver metastases.
Müller H; Nakchbandi W; Chatzissavvidis I; Valek V
Eur J Surg Oncol; 2001 Nov; 27(7):652-61. PubMed ID: 11669594
[TBL] [Abstract][Full Text] [Related]
25. [Infusion chemotherapy and chemoembolization of liver metastases from cancer of the alimentary tract].
Zeng H; Li H; Shi Z
Zhonghua Zhong Liu Za Zhi; 2000 Sep; 22(5):422-4. PubMed ID: 11778283
[TBL] [Abstract][Full Text] [Related]
26. Somatostatin receptor scintigraphy in gastrinomas.
Jensen RT; Gibril F
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S179-85. PubMed ID: 10604126
[TBL] [Abstract][Full Text] [Related]
27. Carcinoid of the pancreas.
Migliori M; Tomassetti P; Lalli S; Casadei R; Santini D; Corinaldesi R; Gullo L
Pancreatology; 2002; 2(2):163-6. PubMed ID: 12123097
[TBL] [Abstract][Full Text] [Related]
28. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.
Wolin EM; Jarzab B; Eriksson B; Walter T; Toumpanakis C; Morse MA; Tomassetti P; Weber MM; Fogelman DR; Ramage J; Poon D; Gadbaw B; Li J; Pasieka JL; Mahamat A; Swahn F; Newell-Price J; Mansoor W; Öberg K
Drug Des Devel Ther; 2015; 9():5075-86. PubMed ID: 26366058
[TBL] [Abstract][Full Text] [Related]
29. Hepatic arterial chemoembolization for metastatic endocrine tumors.
Stokes KR; Stuart K; Clouse ME
J Vasc Interv Radiol; 1993; 4(3):341-5. PubMed ID: 8390317
[TBL] [Abstract][Full Text] [Related]
30. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors.
Clouse ME; Perry L; Stuart K; Stokes KR
Digestion; 1994; 55 Suppl 3():92-7. PubMed ID: 7698544
[TBL] [Abstract][Full Text] [Related]
31. Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumours.
Marrache F; Vullierme MP; Roy C; El Assoued Y; Couvelard A; O'Toole D; Mitry E; Hentic O; Hammel P; Lévy P; Ravaud P; Rougier P; Ruszniewski P
Br J Cancer; 2007 Jan; 96(1):49-55. PubMed ID: 17164755
[TBL] [Abstract][Full Text] [Related]
32. Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs.
Imam H; Eriksson B; Lukinius A; Janson ET; Lindgren PG; Wilander E; Oberg K
Acta Oncol; 1997; 36(6):607-14. PubMed ID: 9408151
[TBL] [Abstract][Full Text] [Related]
33. Carcinoid tumour management in haemodialysis: a case report.
Burke MT; Gray NA
Nephrology (Carlton); 2012 Feb; 17(2):198. PubMed ID: 22257155
[No Abstract] [Full Text] [Related]
34. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors.
Ricci S; Antonuzzo A; Galli L; Orlandini C; Ferdeghini M; Boni G; Roncella M; Mosca F; Conte PF
Am J Clin Oncol; 2000 Aug; 23(4):412-5. PubMed ID: 10955874
[TBL] [Abstract][Full Text] [Related]
35. [Digestive system carcinoid tumors: treatment].
Madeira I; Ruszniewski P
Rev Med Interne; 1999 May; 20(5):421-6. PubMed ID: 10365413
[TBL] [Abstract][Full Text] [Related]
36. Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors.
Palazzo M; Lombard-Bohas C; Cadiot G; Matysiak-Budnik T; Rebours V; Vullierme MP; Couvelard A; Hentic O; Ruszniewski P
Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):232-8. PubMed ID: 23108416
[TBL] [Abstract][Full Text] [Related]
37. Transcatheter chemoembolization of progressive carcinoid liver metastasis.
Therasse E; Breittmayer F; Roche A; De Baere T; Indushekar S; Ducreux M; Lasser P; Elias D; Rougier P
Radiology; 1993 Nov; 189(2):541-7. PubMed ID: 7692465
[TBL] [Abstract][Full Text] [Related]
38. Intermittent treatment of recurrent type-1 gastric carcinoids with somatostatin analogues in patients with chronic autoimmune atrophic gastritis.
Massironi S; Zilli A; Fanetti I; Ciafardini C; Conte D; Peracchi M
Dig Liver Dis; 2015 Nov; 47(11):978-83. PubMed ID: 26321479
[TBL] [Abstract][Full Text] [Related]
39. Slow-release lanreotide treatment in endocrine gastrointestinal tumors.
Tomassetti P; Migliori M; Gullo L
Am J Gastroenterol; 1998 Sep; 93(9):1468-71. PubMed ID: 9732927
[TBL] [Abstract][Full Text] [Related]
40. [Pancreatic endocrine tumor with metastases and increase of alpha-fetoprotein. A case report].
Congy F; Pelletier S; Langlois P; Khayat D; Homsi T; Emerit J
Rev Med Interne; 1992 Nov; 13(6):451-3. PubMed ID: 1285358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
